Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.

IF 8 1区 医学 Q1 CLINICAL NEUROLOGY
Cinta Lleixà, Elba Pascual-Goñi, Lorena Martín-Aguilar, Marta Caballero-Ávila, Roger Collet-Vidiella, Clara Tejada-Illa, Paula Llarch, Eduard Gallardo, Gemma Boera-Carnicero, Verónica Calahorro, Ilaria Callegari, Andrea Cortese, Emilien Delmont, Jerome Devaux, Claudia C Giannotta, Eduardo Nobile-Orazio, Romana Höftberger, Johann Sellner, Sarah Andrée Annie J Herdewyn, Carvajal Alejandra, Laura Torné, Ivonne Jericó, Simon Rinaldi, Claudia Sommer, Kathrin Doppler, Thais Armangue, Maarten J Titulaer, Bart C Jacobs, Ruth Huizinga, Julia V Wanschitz, Nicolau Ortiz Castellon, Davide Sparasci, Paolo Ripellino, Helena Pérez-Pérez, Alejandro Horga, Alicia Alonso-Jiménez, Jonathan De Winter, Amaia Jauregui, Oscar de la Calle-Martin, Laura Martinez-Martinez, Luis Querol
{"title":"Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.","authors":"Cinta Lleixà, Elba Pascual-Goñi, Lorena Martín-Aguilar, Marta Caballero-Ávila, Roger Collet-Vidiella, Clara Tejada-Illa, Paula Llarch, Eduard Gallardo, Gemma Boera-Carnicero, Verónica Calahorro, Ilaria Callegari, Andrea Cortese, Emilien Delmont, Jerome Devaux, Claudia C Giannotta, Eduardo Nobile-Orazio, Romana Höftberger, Johann Sellner, Sarah Andrée Annie J Herdewyn, Carvajal Alejandra, Laura Torné, Ivonne Jericó, Simon Rinaldi, Claudia Sommer, Kathrin Doppler, Thais Armangue, Maarten J Titulaer, Bart C Jacobs, Ruth Huizinga, Julia V Wanschitz, Nicolau Ortiz Castellon, Davide Sparasci, Paolo Ripellino, Helena Pérez-Pérez, Alejandro Horga, Alicia Alonso-Jiménez, Jonathan De Winter, Amaia Jauregui, Oscar de la Calle-Martin, Laura Martinez-Martinez, Luis Querol","doi":"10.1212/NXI.0000000000200602","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>This study describes the human leukocyte antigen (HLA) Class II allele frequencies in patients with anti-CNTN1+ and anti-Caspr1+ autoimmune nodopathy (AN).</p><p><strong>Methods: </strong>Forty-four AN patients and 50 seronegative CIDP patients from 19 different European hospitals were included in the study. Thirty AN patients had anti-contactin 1 (CNTN1) antibodies, 11 anti-contactin-associated protein 1 (Caspr1) antibodies, and 3 had antibodies against both proteins. HLA-DRB1 was genotyped at the 4-digit allele levels, and the percentage of individuals carrying each allele was compared with that of the general population, obtained from the <i>Allele frequencies</i> database.</p><p><strong>Results: </strong>HLA-DRB1*11 alleles appeared in higher proportions in anti-CNTN1+ patients than in seronegative CIDP patients and in the general population (46.7% vs 18% vs 28.4%), with an odds ratio of 3.99 (CI = 1.44 to 11.03, <i>p</i> = 0.01) and 2.2 (CI = 1.07 to 4.53, <i>p</i> = 0.04), respectively. HLA-DRB1*03:01 alleles appeared in significantly higher proportions in anti-Caspr1+ patients than in CIDP patients and in the general population (64.3% vs 22% vs 24.2%), with an odds ratio of 6.38 (CI = 1.77 to 22.99, <i>p</i> = 0.007) and 5.64 (CI = 1.876 to 16.96, <i>p</i> = 0.002), respectively. In the anti-Caspr1+ group, we included 3 patients presenting with antibodies against both CNTN1 and Caspr1 proteins in the acute phase, in which the anti-CNTN1 antibodies disappeared in the chronic phase.</p><p><strong>Discussion: </strong>HLA-DRB1*11 alleles are associated with the detection of anti-CNTN1 antibodies in AN patients, and HLA-DRB1*03:01 alleles associate with anti-Caspr1 antibodies. In addition, our study suggests that antiparanodal antibodies targeting both Caspr1 and CNTN1 are present in a small number of patients with AN. These data reinforce the idea that these patients represent specific subsets with clinical features and risk factors that differ from seronegative CIDP patients and from other AN patients. However, further studies should address the functional relevance of these associations and their pathophysiologic implications.</p>","PeriodicalId":19472,"journal":{"name":"Neurology® Neuroimmunology & Neuroinflammation","volume":"13 4","pages":"e200602"},"PeriodicalIF":8.0000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13293632/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology® Neuroimmunology & Neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXI.0000000000200602","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: This study describes the human leukocyte antigen (HLA) Class II allele frequencies in patients with anti-CNTN1+ and anti-Caspr1+ autoimmune nodopathy (AN).

Methods: Forty-four AN patients and 50 seronegative CIDP patients from 19 different European hospitals were included in the study. Thirty AN patients had anti-contactin 1 (CNTN1) antibodies, 11 anti-contactin-associated protein 1 (Caspr1) antibodies, and 3 had antibodies against both proteins. HLA-DRB1 was genotyped at the 4-digit allele levels, and the percentage of individuals carrying each allele was compared with that of the general population, obtained from the Allele frequencies database.

Results: HLA-DRB1*11 alleles appeared in higher proportions in anti-CNTN1+ patients than in seronegative CIDP patients and in the general population (46.7% vs 18% vs 28.4%), with an odds ratio of 3.99 (CI = 1.44 to 11.03, p = 0.01) and 2.2 (CI = 1.07 to 4.53, p = 0.04), respectively. HLA-DRB1*03:01 alleles appeared in significantly higher proportions in anti-Caspr1+ patients than in CIDP patients and in the general population (64.3% vs 22% vs 24.2%), with an odds ratio of 6.38 (CI = 1.77 to 22.99, p = 0.007) and 5.64 (CI = 1.876 to 16.96, p = 0.002), respectively. In the anti-Caspr1+ group, we included 3 patients presenting with antibodies against both CNTN1 and Caspr1 proteins in the acute phase, in which the anti-CNTN1 antibodies disappeared in the chronic phase.

Discussion: HLA-DRB1*11 alleles are associated with the detection of anti-CNTN1 antibodies in AN patients, and HLA-DRB1*03:01 alleles associate with anti-Caspr1 antibodies. In addition, our study suggests that antiparanodal antibodies targeting both Caspr1 and CNTN1 are present in a small number of patients with AN. These data reinforce the idea that these patients represent specific subsets with clinical features and risk factors that differ from seronegative CIDP patients and from other AN patients. However, further studies should address the functional relevance of these associations and their pathophysiologic implications.

自身免疫性结节病中特异性HLA-DRB1等位基因与抗caspr1和抗cntn1自身抗体相关
背景和目的:本研究描述了人类白细胞抗原(HLA) II类等位基因在抗cntn1 +和抗caspr1 +自身免疫性淋巴结病(AN)患者中的频率。方法:选取欧洲19家医院的44例AN患者和50例血清阴性的CIDP患者作为研究对象。30例AN患者有抗接触蛋白1 (CNTN1)抗体,11例有抗接触蛋白相关蛋白1 (Caspr1)抗体,3例有抗两种蛋白的抗体。HLA-DRB1在4位等位基因水平上进行基因分型,并将携带每个等位基因的个体百分比与从等位基因频率数据库中获得的普通人群百分比进行比较。结果:HLA-DRB1*11等位基因在抗cntn1 +患者中的出现比例高于血清阴性CIDP患者和普通人群(46.7% vs 18% vs 28.4%),优势比分别为3.99 (CI = 1.44 ~ 11.03, p = 0.01)和2.2 (CI = 1.07 ~ 4.53, p = 0.04)。HLA-DRB1*03:01等位基因在抗caspr1 +患者中的出现比例明显高于CIDP患者和普通人群(64.3% vs 22% vs 24.2%),优势比分别为6.38 (CI = 1.77 ~ 22.99, p = 0.007)和5.64 (CI = 1.876 ~ 16.96, p = 0.002)。在抗Caspr1+组中,我们纳入了3例在急性期同时出现CNTN1和Caspr1蛋白抗体的患者,其中抗CNTN1抗体在慢性期消失。讨论:HLA-DRB1*11等位基因与AN患者抗cntn1抗体的检测相关,HLA-DRB1*03:01等位基因与抗caspr1抗体相关。此外,我们的研究表明,针对Caspr1和CNTN1的抗副淋巴结抗体存在于少数AN患者中。这些数据强化了这样一种观点,即这些患者代表了具有不同于血清阴性CIDP患者和其他AN患者的临床特征和危险因素的特定亚群。然而,进一步的研究应该解决这些关联的功能相关性及其病理生理意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
2.30%
发文量
219
审稿时长
8 weeks
期刊介绍: Neurology Neuroimmunology & Neuroinflammation is an official journal of the American Academy of Neurology. Neurology: Neuroimmunology & Neuroinflammation will be the premier peer-reviewed journal in neuroimmunology and neuroinflammation. This journal publishes rigorously peer-reviewed open-access reports of original research and in-depth reviews of topics in neuroimmunology & neuroinflammation, affecting the full range of neurologic diseases including (but not limited to) Alzheimer's disease, Parkinson's disease, ALS, tauopathy, and stroke; multiple sclerosis and NMO; inflammatory peripheral nerve and muscle disease, Guillain-Barré and myasthenia gravis; nervous system infection; paraneoplastic syndromes, noninfectious encephalitides and other antibody-mediated disorders; and psychiatric and neurodevelopmental disorders. Clinical trials, instructive case reports, and small case series will also be featured.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书